Calcineurin Inhibitors

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Interstitial Lung DiseaseDermatitis, Atopic

38 competitors in Interstitial Lung Disease

#DrugCompanyPhaseTrials

1

Rituxan

Roche

Approved

52

Tracleer

Johnson & Johnson

Approved

33

Medrol

Pfizer

Approved

24

Trexall

Jazz Pharmaceuticals

Approved

25

Esbriet

LLegacy Health System

Approved

56

Cytoxan

BBaxter Healthcare Corporation

Approved

37

Actemra

CCelltrion

Approved

28

Cellcept

Roche

Phase 3

49

Imuran

LLegacy Health System

Approved

—10

Ofev

Boehringer Ingelheim

Phase 3

13Show 22 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Prurigo Nodularis2 trials

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)

Completed·Sanofi·Phase 3·NCT04202679·160 enrolled

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

Completed·Sanofi·Phase 3·NCT04183335·151 enrolled

Dermatitis, Atopic2 trials

A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants of Previous Amlitelimab Clinical Trials in Moderate to Severe Atopic Dermatitis.

Active, not recruiting·Sanofi·Preclinical·NCT05492578·1,856 enrolled

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

Completed·Sanofi·Phase 3·NCT06224348·643 enrolled

Pneumonia1 trial

Basiliximab Treating Interstitial Pneumonia of CADM

Unknown status·RRenJi Hospital·Phase 2·NCT03192657·100 enrolled

Monoclonal1 trial

MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT02241018·200 enrolled

Hematopoietic Stem Cell Transplantation1 trial

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Completed·RRegimmune Corporation·Phase 1/2·NCT01379209·68 enrolled

6 more indications

Kidney Transplant1 trial

Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients

Completed·Roche·Phase 4·NCT00121810·305 enrolled

Renal Transplant Recipients1 trial

ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients

Completed·Novartis·Phase 4·NCT00170846·394 enrolled

Post-Transplant Lymphoproliferative Disorder1 trial

Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients

Completed·Bristol-Myers Squibb··NCT01656343·775 enrolled

Lung Transplantation1 trial

Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation

Completed·Novartis·Phase 4·NCT00377962·282 enrolled

Renal insufficiency1 trial

RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency

Completed·Novartis·Phase 3·NCT00267189·145 enrolled

Interstitial Lung Disease1 trial

A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome

Not yet recruiting·—·N/A·NCT07406932·80 enrolled

Details

Drug Info

Related News